The Affiliated Drum Tower Hospital of Nanjing University , School of Medicine, Nanjing, People's Republic of China .
J Endourol. 2014 Jan;28(1):4-9. doi: 10.1089/end.2013.0397. Epub 2013 Nov 20.
To assess the functional and oncologic outcomes of laparoscopic radiofrequency ablation (RFA) with intraoperative contrast-enhanced ultrasonography in treatment of T1b renal tumors.
We performed a retrospective review of 51 patients with unilateral T1b renal tumors who underwent laparoscopic RFA from January 2007 to April 2012 with a mean follow-up of 31.5 months. The tumors were laparoscopically dissected and ablated with cool-tip RFA system under the guidance of contrast-enhanced ultrasound. Routine follow-up included contrast-enhanced computed tomography/magnetic resonance imaging (CT/MRI) and renal function tests.
Mean diameter of the treated renal tumors was 5.1 cm (range 4.1-6.4 cm). Initial ablation success rate was 46/51 (90.2%). Of five incompletely ablated patients, four experienced up to two additional sessions of percutaneous RFA and achieved complete ablation. After at least 12 months contrast-enhanced CT/MRI follow-up after RFA, one patient experienced local tumor recurrence and another developed pulmonary and bone metastases. The 3-year disease-free survival in patients with biopsy-proven cancer was 85.7%. There was no significant difference between the estimated glomerular filtration rate (eGFR) pre- and post-RFA. Mean change in eGFR following RFA was -2.2 mL/minute. No patients required dialysis in the periprocedural period. Major complications (≥Grade 3) only developed in two (3.9%) cases.
Our initial experience with this technique in T1b renal tumors was favorable with good renal function preservation and oncologic outcomes. It may be a good alternative to partial nephrectomy for selected T1b renal tumors.
评估术中超声造影引导下腹腔镜射频消融(RFA)治疗 T1b 期肾肿瘤的功能和肿瘤学结果。
我们回顾性分析了 2007 年 1 月至 2012 年 4 月期间 51 例接受腹腔镜 RFA 治疗的单侧 T1b 期肾肿瘤患者的资料,平均随访 31.5 个月。在超声造影引导下,使用冷尖端 RFA 系统对肿瘤进行腹腔镜下解剖和消融。常规随访包括增强 CT/MRI 检查和肾功能检查。
治疗肾肿瘤的平均直径为 5.1cm(范围 4.1-6.4cm)。初始消融成功率为 46/51(90.2%)。5 例未完全消融的患者中,4 例接受了多达 2 次经皮 RFA 治疗,均达到完全消融。RFA 后至少 12 个月增强 CT/MRI 随访,1 例患者局部肿瘤复发,另 1 例发生肺和骨转移。经活检证实为癌症的患者 3 年无病生存率为 85.7%。RFA 前后肾小球滤过率(eGFR)无显著差异。RFA 后 eGFR 平均下降 2.2mL/min。围手术期无患者需要透析。仅 2 例(3.9%)发生严重并发症(≥3 级)。
我们在 T1b 期肾肿瘤中应用该技术的初步经验是良好的,肾功能保留和肿瘤学结果均令人满意。对于某些 T1b 期肾肿瘤,它可能是肾部分切除术的良好替代方法。